Clinical trials: Mental Depression
Major Depressive Disorder (MDD)
A Study of KH607 as Monotherpy in Adults Participants With Major Depressive Disorder
This trial includes a short-term study and a long-term study. The short-term study is a multicenter, randomized, double-blind, placebo-controlled parallel-group study with a 6-week duration.
- Trial name
- NCT07741240
- Testing
- KH607 tablets
- Volunteers
- 232 people
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Major Depressive Disorder
A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder
This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive…
- Trial name
- NCT00095823
- Testing
- Antidepressant + Aripiprazole
- Where
- 20 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Psoriasis
Post-Marketing Surveillance Study of OTEZLA
To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis arthropathica 1.
- Trial name
- NCT03284879
- Where
- Japan
- Volunteers
- 1,086 people
- Sponsor
- Amgen
Major Depressive Disorder
Efficacy and Safety of Lu AA34893 in Patients With Major Depressive Disorder
The purpose of the study is to evaluate the efficacy, safety and tolerability of three fixed dosages of Lu AA34893 compared to placebo in the treatment of patients with Major Depressive Disorder.
- Trial name
- NCT00766870
- Testing
- Lu AA34893, Venlafaxine extended release
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Efficacy and Safety Study of ABT-436 in Major Depressive Disorder
The purpose is to study the efficacy and safety of ABT-436 in Major Depressive Disorder.
- Trial name
- NCT01741142
- Testing
- ABT-436, Escitalopram
- Where
- 18 sites in United States
- Volunteers
- 19 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Depression, Cognition
Study of Duloxetine in Elderly Patients With Major Depressive Disorder
A study of the safety and efficacy of duloxetine in elderly patients (greater than 65 years old) with major depressive disorder
- Trial name
- NCT00062673
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 311 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder (MDD)
Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)
The purpose of the study is to demonstrate that the efficacy and safety of deep brain rTMS, (Transcranial Magnetic Stimulation) H7-Coil treatment as add on treatment, is as good as the FDA cleared, H1-Coil, in subjects with major…
- Trial name
- NCT03012724
- Testing
- H7-Coil, H1-Coil
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 106 people
- Sponsor
- Brainsway
Depressive Episodes, Bipolar I Depression
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.
A clinical trial to study the efficacy and safety of an investigational drug in people with major depressive episodes associated with with Bipolar I disorder (bipolar I depression) Participants in the study will either receive…
- Trial name
- NCT05169710
- Testing
- SEP-4199 CR 200 mg, SEP-4199 CR 400 mg
- Where
- 89 sites in United States, Bulgaria and 4 more
- Volunteers
- 83 people
- Sponsor
- Sumitomo Pharma America, Inc.
Major Depressive Disorder
The Effect of tDCS in Patients With Moderate to Severe Major Depressive Disorder
Study Type: Interventional Study Design: Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)…
- Trial name
- NCT02657980
- Testing
- Yband(YDT-201N)
- Where
- South Korea
- Volunteers
- 96 people
- Sponsor
- Ybrain Inc.
Depressive Disorder, Treatment-Resistant
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either…
- Trial name
- TRANSFORM-3 (NCT02422186)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 69 sites in United States, Belgium and 10 more
- Volunteers
- 139 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study
The purpose of this study is to determine the long-term safety and tolerability of vortioxetine, once daily (QD), in participants with major depressive disorder.
- Trial name
- NCT01152996
- Testing
- Vortioxetine
- Volunteers
- 1,075 people
- Sponsor
- Takeda
Bipolar I Disorder, Mania
A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
1) To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/day compared with placebo in prevention of relapse in patients with bipolar I disorder whose current episode (i.e.
- Conditions
- Bipolar I Disorder, Mania, Depression
- Trial name
- NCT03573297
- Testing
- Cariprazine
- Where
- 108 sites in United States, Bulgaria and 9 more
- Volunteers
- 901 people
- Sponsor
- AbbVie
Major Depressive Disorder
A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol
The purpose of this study is to determine the effect of LY2216684 on heart rate of participants receiving Albuterol and Propranolol. Information about any side effects that may occur will also be collected.
- Trial name
- NCT01263197
- Testing
- LY2216684, albuterol, propranolol
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)
This study will evaluate the efficacy, safety, and tolerability of adjunctive ALKS 5461 in adults who have treatment refractory MDD.
- Trial name
- NCT03188185
- Testing
- ALKS 5461
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 278 people
- Sponsor
- Alkermes, Inc.
Treatment Resistant Depression
BPL-003 Efficacy and Safety in Treatment Resistant Depression
This is a Phase 2 study randomized, quadruple-masked, multi-center trial with an open-label extension (OLE), designed to investigate the efficacy and safety of BPL-003 in patients with treatment resistant depression (TRD).
- Trial name
- NCT05870540
- Testing
- BPL-003
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 196 people
- Sponsor
- Beckley Psytech Limited
Depression
Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorder
Prospective, multicenter, non-comparative, observational program to describe prevalence of depressive symptoms in a variety of neurological disorders and effects of Fevarin® on the severity of anxiety and depression, sleep state…
- Trial name
- FRIENDS (NCT02043197)
- Where
- 29 sites in Russia
- Volunteers
- 300 people
- Sponsor
- Abbott
Depressive Disorder, Major
Zelquistinel in the Treatment of Major Depressive Disorder
The purpose of this study is to evaluate the efficacy at 1 day post initial oral dose of zelquistinel (AGN-241751) compared with placebo in participants with Major Depressive Disorder (MDD).
- Trial name
- AGN-241751 (NCT03586427)
- Testing
- AGN-241751
- Where
- 25 sites in United States
- Volunteers
- 251 people
- Sponsor
- Syndeio Biosciences, Inc
Depressive Disorder, Major
Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response
This study is designed to determine the safety and effectiveness of vilazodone for major depressive disorder and to discover genetic markers associated with response. This study will enroll approximately 400 patients.
- Trial name
- NCT00285376
- Testing
- vilazodone
- Where
- 15 sites in United States
- Volunteers
- 410 people
- Sponsor
- Genaissance Pharmaceuticals
Bipolar Depression
Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
The study will evaluate the efficacy and safety of ITI-007 in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major…
- Trial name
- NCT03249376
- Testing
- Lumateperone
- Where
- 47 sites in United States, Bulgaria and 4 more
- Volunteers
- 381 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Healthy Male
Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart
This is a two part study. Part A will determine the maximum tolerated dose of TC-5214 administered to healthy male subjects in single ascending oral doses.
- Trial name
- NCT01359618
- Testing
- TC-5214, Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.